Daré Q3 cash $40.4M; Ovaprene IDE approved; DARE-HRT1 positive efficacy data

Dare Bioscience, Inc.

2022-Q3 EPS reported -$0.18 revenue$10,000,000

Cash $40.4M at Sep 30, 2022 vs $51.7M Dec 31, 2021; R&D expense $4.5M (down from $10.4M).
FDA approved IDE for Ovaprene pivotal Phase 3 contraceptive study; investigator meeting Dec 2022.
Positive topline efficacy data from DARE-HRT1 Phase 1/2 study; PK data expected later Q4 2022.
Sildenafil Cream 3.6% Phase 2b RESPOND subject screening completed; topline data targeted Q2 2023.
XACIATO first commercial sale expected 1H 2023 under Organon license agreement.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Dare Bioscience, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, Dare Bioscience, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001401914-22-000085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.